The identification and the discrimination of autoantibodies against parietal cells (APCA), mitochondria (AMA), liver-kidney microsome type 1 (LKM-1) and smooth muscle (ASMA) through IFA techniques, are important pillars of gastric and liver autoimmune diseases diagnosis, ensuring high valuable medical insights in a cost-efficiency manner.
The combination of gastroscopy and determination of specific autoantibodies is needed for the diagnosis of gastric and hepatic autoimmune diseases:
Comprehensive IFA portfolio completed by Sebia’s ELISA-based random access Monotests for Alegria 2.
Premium tissue sections and homogeneous tissue layer.
of ELISA-based random access Monotests for an economical workflow.
using Alegria 2 ELISA-based random access analyzer or IFA processor dIFine® P30 and dIFine® automated microscope.
Mouse Liver/Kidney/Stomach Tissue is designed for the qualitative and semi-quantitative detection of antinuclear, mitochondrial (AMA), smooth muscle (ASMA), parietal cell (APCA) and liver-kidney microsome type 1 (LKM-1) antibodies by the indirect fluorescent antibody IFA technique.
The identification and discrimination of AMA, ASMA, APCA and LKM-1 autoantibodies through IFA techniques, are important pillars of gastric and liver autoimmune diseases diagnosis in conjunction with other laboratory and clinical findings.
Rat Kidney/Stomach Tissue is designed for the qualitative and semi-quantitative detection of antinuclear, mitochondrial, smooth muscle and parietal cell antibodies by the indirect fluorescent antibody IFA technique.
The identification and discrimination of AMA, ASMA, APCA and LKM-1 autoantibodies through IFA techniques, are important pillars of gastric and liver autoimmune diseases diagnosis in conjunction with other laboratory and clinical findings.
Rat Kidney/Stomach/Liver Tissue is designed for the qualitative and semi-quantitative detection of antinuclear, mitochondrial, smooth muscle and parietal cell antibodies by the indirect fluorescent antibody IFA technique.
The identification and discrimination of AMA, ASMA, APCA and LKM-1 autoantibodies through IFA techniques, are important pillars of gastric and liver autoimmune diseases diagnosis in conjunction with other laboratory and clinical findings.
AMA-M2 is an immunoassay for the in vitro determination of IgG autoantibodies against mitochondrial M2 subtype antigen in human serum samples.
The test is intended to aid in the diagnosis of primary biliary cholangitis (PBC) in conjunction with other laboratory and clinical findings.
Anti-BPI is an immunoassay for the in vitro determination of IgG autoantibodies against bactericidal permeability-increasing protein (BPI) in human serum samples.
The test is intended to aid in the diagnosis of chronic bowel inflammatory conditions like ulcerative colitis (UC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) type 1 in conjunction with other laboratory and clinical findings.
Anti-Cathepsin G is an immunoassay for the in vitro determination of IgG autoantibodies against cathepsin G in human serum samples.
The test is intended to aid in the diagnosis of CTD and other related inflammatory rheumatic disorders in conjunction with other laboratory and clinical findings.
Anti-gp210 is an immunoassay for the in vitro determination of IgG autoantibodies against gp210 in human serum samples.
The test is intended to aid in the diagnosis of primary biliary cholangitis (PBC) in conjunction with other laboratory and clinical findings.
Anti-Intrinsic Factor is an immunoassay for the in vitro determination of IgG autoantibodies against intrinsic factor in human serum samples.
The test is intended to aid in the diagnosis of autoimmune gastritis and pernicious anaemia in conjunction with other laboratory and clinical findings.
Anti-Lactoferrin is an immunoassay for the in vitro determination of IgG autoantibodies against lactoferrin in human serum samples.
The test is intended to aid in the diagnosis of the chronic bowel inflammatory condition ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) in conjunction with other laboratory and clinical findings.
Anti-LC1 is an immunoassay for the in vitro determination of IgG autoantibodies against liver cytosolic antigen-1 (LC1) in human serum samples.
The test is intended to aid in the diagnosis of autoimmune hepatitis (AIH) type 2 in conjunction with other laboratory and clinical findings.
Anti-LKM-1 is an immunoassay for the in vitro determination of IgG autoantibodies against liver-kidney microsomal 1 (LKM-1) in human serum samples.
The test is intended to aid in the diagnosis of autoimmune hepatitis (AIH) type 2 in conjunction with other laboratory and clinical findings.
Anti-Lysozyme is an immunoassay for the in vitro determination of IgG autoantibodies against lysozyme in human serum samples.
The test is intended to aid in the diagnosis of chronic bowel inflammatory conditions like ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) in conjunction with other laboratory and clinical findings.
Anti-Parietal Cell is an immunoassay for the in vitro determination of IgG autoantibodies against alpha- and beta-subunits of the parietal cell H+/K+-ATPase in human serum samples.
The test is intended to aid in the diagnosis of autoimmune gastritis and pernicious anaemia in conjunction with other laboratory and clinical findings.
Anti-SLA is an immunoassay for the in vitro determination of IgG autoantibodies against soluble-liver antigen (SLA) in human serum samples.
The test is intended to aid in the diagnosis of autoimmune hepatitis (AIH) type 1 in conjunction with other laboratory and clinical findings.
Anti-Sp100 is an immunoassay for the in vitro determination of IgG autoantibodies against Sp100 in human serum samples.
The test is intended to aid in the diagnosis of primary biliary cholangitis (PBC) in conjunction with other laboratory and clinical findings.
ASCA immunoassays are used for the in vitro determination of respective antibody isotypes against Saccharomyces cerevisiae (ASCA) in human serum samples.
The tests are intended to aid in the diagnosis of chronic bowel inflammatory conditions (Crohn’s disease) in conjunction with other laboratory and clinical findings.
ASCA IgA
ASCA IgG
ASCA IgG/IgA
Small footprint – Big impact.
Obtain your patients results with high flexibility reliability and efficiency with Alegria 2.
The Alegria 2 provides the possibility of giving results to clinicians within a timeframe fitting clinical needs and helps to optimize the patient’s care pathway.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.